Cargando…

The Incidence and Risk Factors of Urinary Tract Infection in Patients with Type 2 Diabetes Mellitus Using SGLT2 Inhibitors: A Real-World Observational Study

Background: The incidence and risk of urinary tract infection (UTI) in patients with type 2 diabetes mellitus (T2DM) who use sodium glucose co-transporter-2 (SGLT2) inhibitors are still controversial. Therefore, this study aimed to investigate the incidence and risk factors of using SGLT2 inhibitors...

Descripción completa

Detalles Bibliográficos
Autores principales: Uitrakul, Suriyon, Aksonnam, Krittika, Srivichai, Pimchanok, Wicheannarat, Sorawit, Incomenoy, Supatcha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9785475/
https://www.ncbi.nlm.nih.gov/pubmed/36547992
http://dx.doi.org/10.3390/medicines9120059
_version_ 1784858057810903040
author Uitrakul, Suriyon
Aksonnam, Krittika
Srivichai, Pimchanok
Wicheannarat, Sorawit
Incomenoy, Supatcha
author_facet Uitrakul, Suriyon
Aksonnam, Krittika
Srivichai, Pimchanok
Wicheannarat, Sorawit
Incomenoy, Supatcha
author_sort Uitrakul, Suriyon
collection PubMed
description Background: The incidence and risk of urinary tract infection (UTI) in patients with type 2 diabetes mellitus (T2DM) who use sodium glucose co-transporter-2 (SGLT2) inhibitors are still controversial. Therefore, this study aimed to investigate the incidence and risk factors of using SGLT2 inhibitors, particularly in Thai patients. Methods: Electronic medication records of all patients, who started the treatment of T2DM between 1 January 2019 and 30 June 2021 at a tertiary hospital in Thailand, were reviewed. The patients were divided into SGLT2 inhibitor and non-SGLT2 inhibitor groups to compare the incidence of UTI. Results: The overall incidence rate of UTI was 33.49% in the SGLT2 inhibitor group and 11.72% in the non-SGLT2 inhibitor group. The incidence rates of UTI were not different between dapagliflozin and empagliflozin treatment (34.00% and 33.03%, respectively). Patients treated with SGLT2 inhibitors had a 3.70 higher risk of UTI compared with those treated with non-SGLT2 inhibitors (95%CI 2.60–5.29). Moreover, the significant risk factors for UTI found in this study were gender, age, and occupation. Conclusions: This study highlighted the high incidence of UTI in patients using dapagliflozin and empagliflozin compared with non-SGLT2 inhibitors. Additionally, patients of female gender and older age had a significantly higher risk of UTI when treated with SGLT2 inhibitors, whereas those with permanent jobs had a lower risk.
format Online
Article
Text
id pubmed-9785475
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-97854752022-12-24 The Incidence and Risk Factors of Urinary Tract Infection in Patients with Type 2 Diabetes Mellitus Using SGLT2 Inhibitors: A Real-World Observational Study Uitrakul, Suriyon Aksonnam, Krittika Srivichai, Pimchanok Wicheannarat, Sorawit Incomenoy, Supatcha Medicines (Basel) Article Background: The incidence and risk of urinary tract infection (UTI) in patients with type 2 diabetes mellitus (T2DM) who use sodium glucose co-transporter-2 (SGLT2) inhibitors are still controversial. Therefore, this study aimed to investigate the incidence and risk factors of using SGLT2 inhibitors, particularly in Thai patients. Methods: Electronic medication records of all patients, who started the treatment of T2DM between 1 January 2019 and 30 June 2021 at a tertiary hospital in Thailand, were reviewed. The patients were divided into SGLT2 inhibitor and non-SGLT2 inhibitor groups to compare the incidence of UTI. Results: The overall incidence rate of UTI was 33.49% in the SGLT2 inhibitor group and 11.72% in the non-SGLT2 inhibitor group. The incidence rates of UTI were not different between dapagliflozin and empagliflozin treatment (34.00% and 33.03%, respectively). Patients treated with SGLT2 inhibitors had a 3.70 higher risk of UTI compared with those treated with non-SGLT2 inhibitors (95%CI 2.60–5.29). Moreover, the significant risk factors for UTI found in this study were gender, age, and occupation. Conclusions: This study highlighted the high incidence of UTI in patients using dapagliflozin and empagliflozin compared with non-SGLT2 inhibitors. Additionally, patients of female gender and older age had a significantly higher risk of UTI when treated with SGLT2 inhibitors, whereas those with permanent jobs had a lower risk. MDPI 2022-11-22 /pmc/articles/PMC9785475/ /pubmed/36547992 http://dx.doi.org/10.3390/medicines9120059 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Uitrakul, Suriyon
Aksonnam, Krittika
Srivichai, Pimchanok
Wicheannarat, Sorawit
Incomenoy, Supatcha
The Incidence and Risk Factors of Urinary Tract Infection in Patients with Type 2 Diabetes Mellitus Using SGLT2 Inhibitors: A Real-World Observational Study
title The Incidence and Risk Factors of Urinary Tract Infection in Patients with Type 2 Diabetes Mellitus Using SGLT2 Inhibitors: A Real-World Observational Study
title_full The Incidence and Risk Factors of Urinary Tract Infection in Patients with Type 2 Diabetes Mellitus Using SGLT2 Inhibitors: A Real-World Observational Study
title_fullStr The Incidence and Risk Factors of Urinary Tract Infection in Patients with Type 2 Diabetes Mellitus Using SGLT2 Inhibitors: A Real-World Observational Study
title_full_unstemmed The Incidence and Risk Factors of Urinary Tract Infection in Patients with Type 2 Diabetes Mellitus Using SGLT2 Inhibitors: A Real-World Observational Study
title_short The Incidence and Risk Factors of Urinary Tract Infection in Patients with Type 2 Diabetes Mellitus Using SGLT2 Inhibitors: A Real-World Observational Study
title_sort incidence and risk factors of urinary tract infection in patients with type 2 diabetes mellitus using sglt2 inhibitors: a real-world observational study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9785475/
https://www.ncbi.nlm.nih.gov/pubmed/36547992
http://dx.doi.org/10.3390/medicines9120059
work_keys_str_mv AT uitrakulsuriyon theincidenceandriskfactorsofurinarytractinfectioninpatientswithtype2diabetesmellitususingsglt2inhibitorsarealworldobservationalstudy
AT aksonnamkrittika theincidenceandriskfactorsofurinarytractinfectioninpatientswithtype2diabetesmellitususingsglt2inhibitorsarealworldobservationalstudy
AT srivichaipimchanok theincidenceandriskfactorsofurinarytractinfectioninpatientswithtype2diabetesmellitususingsglt2inhibitorsarealworldobservationalstudy
AT wicheannaratsorawit theincidenceandriskfactorsofurinarytractinfectioninpatientswithtype2diabetesmellitususingsglt2inhibitorsarealworldobservationalstudy
AT incomenoysupatcha theincidenceandriskfactorsofurinarytractinfectioninpatientswithtype2diabetesmellitususingsglt2inhibitorsarealworldobservationalstudy
AT uitrakulsuriyon incidenceandriskfactorsofurinarytractinfectioninpatientswithtype2diabetesmellitususingsglt2inhibitorsarealworldobservationalstudy
AT aksonnamkrittika incidenceandriskfactorsofurinarytractinfectioninpatientswithtype2diabetesmellitususingsglt2inhibitorsarealworldobservationalstudy
AT srivichaipimchanok incidenceandriskfactorsofurinarytractinfectioninpatientswithtype2diabetesmellitususingsglt2inhibitorsarealworldobservationalstudy
AT wicheannaratsorawit incidenceandriskfactorsofurinarytractinfectioninpatientswithtype2diabetesmellitususingsglt2inhibitorsarealworldobservationalstudy
AT incomenoysupatcha incidenceandriskfactorsofurinarytractinfectioninpatientswithtype2diabetesmellitususingsglt2inhibitorsarealworldobservationalstudy